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The B cell-specific activator protein (BSAP) is a DNA-binding transcription factor expressed 
in pro-B, pre-B, and mature B cells, but not in plasma cells. In this study, we explored the role 
of BSAP in B cell function by assessing how the content of this protein varies in cells driven 
by proliferative stimuli and, conversely, how artificial manipulation of BSAP activity affects cell 
proliferation. We found that BSAP activity of nuclear extracts increased when B cells were activated 
by mitogen (lipopolysaccharide [LPS]), antigen receptor-mediated signaling (surface immuno- 
globulin D [IgD] cross-linking) or T cell-dependent stimulation (CD40 cross-linking). We could 
suppress BSAP activity by exposure of B cells to phosphorothioate oligonucleotides  antisense 
to the BSAP translation initiation start site, whereas control oligonudeotides were virtually inactive. 
Antisense-induced  BSAP suppression was associated with a striking reduction in LPS-induced 
proliferation of splenic B cells and in the spontaneous proliferation orb lymphoma cells (CH12.LX), 
but the antisense oligonucleotide had virtually no effect on proliferation of two call lines lacking 
BSAP: the T lymphoma line EL-4 and the plasma cell line MOPC-315. Overexpression of BSAP 
in splenic B cells or de novo expression in MOPC-315  plasma cells induced by transfection  of 
a BSAP expression plasmid stimulated ceU proliferation.  Taken together, these results suggest 
that BSAP activity is a rate-limiting regulator of B cell proliferation. We also found that treatment 
with the antisense BSAP oligonucleotide downregulated Ig class switching induced by interleukin 
4 plus LPS. This effect may be secondary to reduced proliferation or could be mediated through 
BSAP binding sites in the IgH locus. 
A  B cell lineage-specific transcription factor, B cell-specific 
activator  protein (BSAP)  1 (1), was recently found to 
bind in regulatory regions of several B cell-specific genes, 
including the promoters of the CD19 gene (2), the CD20 
gene (J. Kehrl, personal communication), the Vp~r  gene, 
and the )x5 gene (3). In addition, BSAP binding sites have 
been identified in several C. gene intronic regions (4-6), as 
well as at sites 5' to and within the Ig H chain 3'or enhancer 
(7, 8). 
BSAP is encoded by the Pax-5 gene (9) and is a member 
of the Pax gene family of homeodomain class transcription 
factors. All nine Pax genes described so far are important regu- 
lators of development and are highly conserved during evo- 
lution (10, 11). The Pax-5 gene is classified in subclass III 
of these genes (along with Pax-2 and Pax-8;  12), and con- 
rains a bipartite "paired domain" responsible for DNA binding 
1 Abbreviations  used in this paper: BSAP, B ceU-specific activator protein; 
EMSA, electrophoretic  mobility shift assay. 
(9, 13), a sequence encoding a characteristic octapeptide, and 
a homeobox homology region (9). Individual Pax genes are 
temporally and spatially regulated during development: Pax-2 
and Pax-8 are expressed in the developing excretory system 
and in kidney cells that lack BSAP (14, 15). In contrast, BSAP 
(Pax-5) is specifically expressed in the B cell lineage (1, 9). 
Within the B cell lineage, BSAP is found in pro-B, pre-B, 
and mature B cells, but not in plasma cells (1). In addition, 
it is not found in cells of hematopoietic lineage other than 
B cells, but is found in the developing central nervous system 
and adult testis (9,  16). 
In this report we demonstrate that specific downregula- 
tion of BSAP expression is associated with greatly reduced 
B cell proliferation,  whereas upregulation of BSAP expres- 
sion is associated with increased B cell proliferation.  This 
finding,  combined with our recent observation  that BSAP 
negatively regulates the Ig 3'o~ enhancer (8) suggests that 
BSAP regulates the differentiation of mature B cells on sev- 
eral levels, and thus is a key factor controlling B cell differen- 
tiation. 
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Cell Preparation and Culture Conditions.  Purified splenic B cells 
were obtained from 4--8-wk-old female BALB/c mice (NIH stock) 
as follows: (a) splenocyte cell suspensions were depleted of RBCs 
by hypotonic lysis with ACK lysing buffer (B & B/Scott, Fiskeville, 
RI) and of T cells by complement-mediated cytotoxic lysis using 
various mAbs: anti-Thy 1.2 (New England Nuclear, Boston, MA), 
anti-CD3 (2Cll; American Type Culture Collection [ATCC], Rock- 
ville,  ME)), anti-CD4  (RL1724),  and anti-CD8  (3.155) kindly 
provided by Dr. E. Shevach, Laboratory of Immunology, National 
Institute of  Allergy and Infectious Diseases, Bethesda, MD) in con- 
junction with rabbit complement (Low-Tox  M; Cedar Lane, West- 
bury, NY); (b) B cells thus obtained were further selected for high 
density (resting) cells by Percoll-gradient centrifugation (Pharmacia 
Fine Chemicals,  Piscataway, NJ) using cells collected at 60/70% 
layer. B cell lymphoma cells CH12.LX (slgM +) were obtained 
from Dr. G. Hanghton (University of North Carolina, Chapel Hill, 
NC; 17) and maintained in this laboratory for several years. IgA- 
secreting myeloma cells (MOPC-315)  and EL4 thymoma T cells 
were obtained from the ATCC. An L cell line expressing Fc3, II 
receptor  (LcDw32) was  kindly  provided  by  Dr.  Kevin  Moore 
(DNAX,  Palo Alto, CA;  18). 
Cells were maintained in RPMI 1640 supplemented with 10% 
FCS,  5%  NCTC  109  media  (Whittaker  M.  A.  Bioproducts, 
Walkersville, ME)), 20 mM Hepes (Biofluids, Inc., Rockville, MD), 
2 mM L-glutamine (GIBCO BRL, Gaithersburg, MD), and 50/zM 
B-ME (Sigma Chemical Co., St. Louis, MO). MOPC-315 myeloma 
cells were grown in DMEM containing the same ingredients,  ex- 
cept for NCTC. 
Preparation of L  Cells Expressing the CD40 Ligand.  L cells ex- 
pressing the CD40 ligand were prepared as follows. First, DNA 
including the whole coding region of the CD40 ligand, was ob- 
tained by RT-PCR amplification  of RNA extracted from PMA- 
stimulated EL-4 T cells using specific primers (see Table 1) based 
on the published sequence of CD40 ligand (19). Next, the amplified 
product was first cloned into the pCR  TM  II vector (Invitrogen 
Corp., San Diego, CA) then recloned into the pcDNA I neo ex- 
pression plasmid (Invitrogen Corp.), and the recombinant plasmids 
thus obtained were detected by restriction fragment analysis.  Plasmid 
DNA from one such clone was then transfected by electroporation 
into L cells stably transfected with a plasmid expressing the Fc',/II 
receptor CDw32 (18). The ceils were grown in O_,418 (400/zg/ml) 
to select for stably transfected L cells. Finally, stable transformants 
were screened for their ability to induce proliferation  of spleen B 
cells,  and  the  most  potent  cell  line  was  recloned,  designated 
LCD~L, and used in this study. 
Electrophoretic  Mobility Shift Assay.  Nuclear proteins were pre- 
pared from cultured cells as described elsewhere (20). Protein con- 
centrations were measured with the Bradford assay (21). Oligonu- 
cleotides for electrophoretic  mobility shift assays (EMSAs) (Table 
1) were  endlabeled  with 3,-[3Zp]ATP (>5,000  Ci/mmol; Amer- 
sham Corp., Arlington Heights, IL) using bacteriophage T4 poly- 
nucleotide kinase (New England Biolabs Inc., Beverly, MA) and 
gel purified. EMSA reactions contained 1-3 fmol double-stranded 
DNA, 2/zg synthetic DNA duplex of poly (dI-dC) (Pharmacia 
Fine Chemicals),  10 mM Hepes,  pH 7.9,  100 mM NaC1,  10% 
glycerol, 0.5 mM MgC12, and 1 mM dithiothreitol. After prein- 
cubation without protein for 15 min at room temperature,  crude 
nuclear proteins in indicated concentrations were added to the reac- 
tion for an additional 15 min. The mixture was then subjected to 
electrophoresis  on  native  4%  polyacrylamide  gels  in  lx  Tris- 
borate/EDTA (TBE) buffer to separate protein-DNA complexes. 
Finally, the gels were dried and exposed to Kodak films on inten- 
sifying screens overnight at  -80~  Autoradiographs  were ana- 
lyzed by densitometry using Image Quant (Molecular Dynamics, 
Inc.,  Sunnyvale, CA). 
Coincubation with Oligonudeotides.  Phosphorothioate oligonu- 
cleotides were prepared by Genosys Biotechnologies,  Inc. (Wood- 
land, TX). These consisted of 18 mer that were antisense and sense 
for the RNA sequence that spans the translation initiation site of 
murine BSAP (see Table 1; these sequence data are available from 
EMBL/GenBank/DDBJ under accession number M97013). In ad- 
dition, a control (non-sense) oligonucleotide mixture was prepared 
consisting of scrambled 18 mer containing the same G  +  C and 
A + T content of the antisense oligonucleotide (see Table 1). Coin- 
cubation of cells with phosphorothioate oligonucleotides  was per- 
formed as previously described (22). In brief, B cells were washed 
twice with HBSS and Opti-MEM, then cultured in serum-free Opti- 
MEM containing indicated concentrations of oligonucleotides  for 
various lengths of time. 
Proliferation and Viability Assays.  Proliferation  of cells was as- 
sessed by measuring [3H]TdR incorporation during the final 8 h 
of cell culture. In brief, 5  x  104 B cells/ml were cocultured with 
irradiated (10 krad) L cells (5  x  103/ml) in flat-bottomed 96-well 
plates (Costar Corp., Cambridge, MA) for 72 h. During the last 
8 h of culture, 1/~Ci of [3H]TdR (sp act 6.7 Ci/mmol; New En- 
gland Nuclear) was added to each well; incorporated  3H radioac- 
tivity was measured in a scintillation  counter (LS2800; Beckman 
Instruments,  Inc., Fullerton, CA). Each incubation experiment was 
done in triplicate.  The cell viability at the end of culture was as- 
sessed by trypan blue exclusion. 
In experiments  examining the effects of CD40L stimulation, 
resting B cells were cocultured with an indicated  (see Results) 
number of LCD40L  cells. For anti-IgD stimulation, resting B cells 
were cocultured with LcDw32 (5  x  10Vml) in media containing 
10/~g/ml of anti-IgD (AMS 9.1.1.1.; obtained from the ATCC). 
For LPS stimulation, resting B cells were cultured in media con- 
taining 20/~g/ml of Escherichia coli LPS (B4:0111; Sigma Chemical 
Co.);  to  control for the costimulatory activity of the  L cells, 
LCD~2 cells (5  x  103/ml) were included in the LPS-stimulated cell 
cultures. L cells were omitted in the proliferation assays using cell 
lines. In coincubation studies of resting B cells and S-oligonucleo- 
tides, an indicated concentration of oligonucleotides  was added to 
each culture at the start of the culture period. 
Construction of BSAP Expression Plasraid.  cDNA for the coding 
region of BSAP was obtained by subjecting total RNA extracted 
from CH12.LX B cells to RT-PCR using primers (Table 1) derived 
from previously published sequence data (9). The resulting eDNA 
was first cloned into the pCR  TM II vector (Invitrogen Corp.), then 
recloned in sense orientation between the Nod and XhoI sites of 
the  BCMGSNeo eDNA  expression  vector (kindly donated by 
Dr. H. Karasuyama, Basel Institute of Immunology, Basel, twit- 
zerland; 23). The transcription unit of BCMGSNeo consisted of 
the CMV promoter region, a leader sequence interrupted by an 
intron,  a  multiple cloning  site,  and  a  polyadenyhtion signal. 
The BCMGSNeo plasmid containing the BSAP cDNA was desig- 
nated BCMGSNeo-BSAP.  For  control  studies,  a  derivative  of 
the BCMGSNeo plasmid containing a 350-bp  stuffer fragment 
(BCMGSNeo-control)  was also prepared. 
Transfection Conditions,  2  x  107 spleen B cells or MOPC-315 
plasma cells in the logarithmic growth phase were transfected with 
10/zg of the BCMGSNeo-BSAP or BCMGSNeo control plasmid. 
Transfection of plasmids was performed by electroporation in 800 
/~1 phosphate-buffered  sucrose media (272 mM sucrose, 7 mM so- 
dium phosphate,  and 1 mM MgCIz, pH 7.4) using a Gene Pulser 
1100  BSAP  Regulates B Cell Proliferation (Bio-Rad, Richmond, CA) at 300 V and 25 #F capacitance. After 
electroporation, cells were kept for 10 rain on ice and then cul- 
tured in conventional media. 
Enrichment of  Plasraid-transfected  Cells.  Since  only a minority of 
cells are successively  transfected under the above transfection con- 
ditions, an attempt was made to study the proliferation of a cell 
population enriched for transfection-competent calls by marking 
these cells with dextran-FrII2 (24, 25). In these experiments, splenic 
B cells were electroporated with the test plasmids in the presence 
of 0.2 mg/ml of dextran-FITC (10,000 Me; Sigma Chemical Co.). 
The cells were then incubated for 2 h in culture medium, treated 
for 1 min with 0.01% trypsin to remove nonspecifically  bound 
dextran-FITC, and washed three times in HBSS containing 0.1% 
BSA. FinaUy, the ceils were sorted using a FACStar Plus  |  (Becton 
Dickinson & Co., San  Jose, CA). Gates were set by side and forward 
scattergram, as well as with propidium iodide staining to exclude 
dead cells. For sorting, one gate was set to collect the FITC-positive 
cells which appeared in the top 15th percentile of the fluorescence 
intensity histogram. These were labded "FITC-High" cells. An- 
other sorting gate was set to collect the ceils in the lowest 15th 
percentile of the histogram and labeled, "FITC-Low" cells. The 
FITC-High and FITC-Low populations were then cultured sepa- 
rately and assayed  for proliferation as described above. The ability 
of FITC staining to mark transfection-competent  cells was assessed 
by a control experiment in which cells were transfected with 10 
#g/ml of pSV-B-galactosidase Control Vector (Promega Corp., 
Madison, WI) in the presence of dextran-FITC and sorted as de- 
scribed above. After 24 h of culture, both cell populations were 
fixed and incubated with X-Gal, according to the manufacturer's 
protocol, to measure/3-galactosidase expression. 
Flow Cytoraetric  Analysis orb Cell Isotype Switching.  To examine 
oligonucleotide effects  on switching of B cells to IgG1 expression, 
resting B ceils were cultured in media containing LPS (20/~g/ml), 
IL-4 (400 U/ml of raiL-4; C-enzyme  Corp., Cambridge, MA) and 
30 ~M of phosphorothioate oligonudeotides. After 4 d of incuba- 
tion,  the B cells were washed twice in HBSS (Biofluids Inc.), 
resuspended in HBSS containing 0.2% BSA without phenol red 
(NIH Media Unit) and stained with FITC-labeled goat anti-IgG1 
and PE-labeled goat anti-IgM (both obtained from Southern Bio- 
technology Associates, Birmingham, AL). In most cases, 30 #g/ml 
of anti-Fc3,R (2.4G2; Pharmingen, San Diego, CA) was added to 
each tube before addition of  fluorochrome-hbeted  antibodies  to pre- 
vent cytophilic binding of fluorochrome-labeled antibody to the 
cell surface. Propidium iodide (1/~g/ml) was added to the final cell 
suspension so that gates could be set to exclude dead cells. Surface 
immunofluorescence  was assessed using a flow cytometer (EPICS 
753; Coulter Electronics Inc., Hialeah, FL). 
Data Analysis.  Statistical  analysis  was done by the paired Stu- 
dent's t test. 
Results 
BSAP Expression in Resting and Stimulated B Cells.  In ini- 
tial studies, we explored changes in BSAP activity during 
the exposure of routine spleen  B  cells to three activation 
stimuli: (a) CD40 ligand, expressed on the surface of murine 
L cells stably transfected with a CD40 ligand cDNA construct 
(LcD40i.); (b)  monoclonal anti-IgD (AMS9.1.1.1)  bound to 
mouse L cells stably transfected with a gene encoding the 
CDw32 molecule (Fey II receptor)  (Lcnw3z); and (c) LPS (in 
the presence  of Lenw32). As shown in Fig.  1 a,  all  three 
methods of stimulation induced B cell proliferation under 
the culture conditions used. Nuclear proteins extracted from 
B cells stimulated under these conditions were analyzed for 
BSAP content by EMSAs at various time points. As shown 
in Fig. 1 b, BSAP is constitutively expressed in spleen B ceils, 
and all three methods of stimulation induced increases in BSAP 
expression compared with nonstimulated B cells. Quantifica- 
tion of EMSA bands, as shown in Fig. 1 c, revealed that the 
Table  1.  Synthetic Oligonucleotides Used in this Paper 
Reference 
S-oligo DNAs for coincubation study 
Sense oligo DNA:  5'-CGAAATGGATTTAGAGAA-Y 
Andsense oligo DNA:  5'-TTCTCTAAATCCATTTCG-3 
Non-sense (scrambled) oligo DNA: 5'-WRWWKWRRSWRWRWSRWR-Y (W = A + T; K = A + G; S = G + C) 
Double-stranded DNAs for EMSA probes 
H2A-2.2 site: CAGGGTTCTGACGCAGCGGTGGGTGACGACTGTCG 
CTCCCAACACTGCGTCGCCACCCACTGCTGACAGC 
AP-1 site:  CTAGTGATGAGTCAGCCGGATC 
GATCACTACTCAGTCGGCCTAG 
PCR primers 
BSAP cDNA 5' primer:  5'-ATCGTCTCGAGTCATCAAGTCCTGAAATATCG-3' 
BSAP cDNA 3' primer: 5'-TATGCGGCCGCGTCAGCGTCGGTGCAGAGTA-3' 
CD40 ligand 5' primer:  5'-CCCTTAAGCTTGCATGATAGAAACATA-Y 
CD40 ligand 3' primer:  5'-TAGAGCTCGAGGTTCAGAGTTTGAGTAAGCC-3' 
38 
9 
9 
19 
19 
1101  Wakatsuki  et al. Figure  1.  Time course of BSAP 
induction by three different methods 
of B cell stimulation. Percoll gra- 
dient-separated,  small, high density 
(resting) spleen B cells (at 105/ml) 
were stimulated by LPS (20 #g/ml) 
in the presence of L cells expressing 
F~II receptors (LcDw32)  (104/ml); 
LCDw32  stably  transfected  with 
CD40  ligand  (Lcn40t) (104/ml); 
and anti-IgD (10 #g/ml) in the pres- 
ence  of LCDw32 ceils (104/ml).  (a) 
Effect of the three stimuli on B cell 
proliferation. (b) EMSA analysis of 
nuclear proteins extracted from sti- 
muhted B cells for BSAP expression. 
Nuclear proteins were extracted at 
indicated time points and EMSA 
was performed using 5 #g of crude 
nuclear extract and a labeled H2A- 
2.2 BSAP probe.  (c) BSAP EMSA 
signals from b were quantified  by 
densitometry and  the  values  ob- 
tained were plotted as fold increases 
relative to BSAP EMSA signals of 
nonstimulated B cells. 
time course of BSAP expression in stimulated ceUs roughly 
correlated  with  the proliferation  data. 
A  BSAP Antiseme Oligonucleotide  Specifically Reduces BSAP 
Expression and Inhibits LPS-induced B cell Proliferation.  The 
parallel  changes in BSAP activity and proliferation rate ob- 
served after B cell activation with aU three stimuli suggested 
the possibility that BSAP might have a role in the regulation 
of B  cell  proliferation.  We  therefore  investigated  whether 
proliferation could be inhibited by exposing cells to an anti- 
sense oligonucleotide designed to downregulate BSAP expres- 
sion. In these studies, we incubated ceUs with a phosphoro- 
thioate-substituted oligonudeotide that is complementary to 
BSAP mRNA overlapping the translation initiation site (an- 
tisense oligonucleotide,  Table  1), as well as oligonudeotides 
corresponding  to the sense strand sequence (sense oligonu- 
cleotide) and non-sense (scrambled) oligonucleotides having 
the same G  +  C  and A  +  T  composition  as the antisense 
oligonucleotide. As shown in Fig. 2, incubation of LPS-treated 
Figure  2.  Specificity ofdownregulation of BSAP by antisense oligonu- 
deotides. Resting spleen cells were stimulated with LPS in the presence 
of BSAP oligonucleotides (30 #M/ml) (antisense,  sense, and non-sense). 
Nuclear proteins were extracted at days 2 and 3, and analyzed by EMSA 
using labeled oligonucleotides specific for BSAP (H2A-2.2 site) and AP-1 
(see Table 1) as probes. The values in the figure indicate the relative density 
of each retarded band to that of the control (CHI2.LX) obtained by den- 
sitometry of EMSA  signals. 
1102  BSAP Regulates B Cell Proliferation spleen B cells with 30 #m antisense oligonucleotide for 12 h 
significantly reduced the BSAP activity detected  in nuclear 
extracts isolated  from the cells after 2 or 3 d of culture,  in 
comparison to the activity from cells incubated with the sense 
olignnucleotide or the non-sense (scrambled)  oligonucleo- 
tides. This effect was specific for BSAP, as the antisense oli- 
gonucleotide had no effect on the AP-1 activity in the same 
extracts  (Fig.  2,  bottom). 
Having demonstrated  the ability of antisense oligonudeo- 
tides to dowuregulate BSAP, we then determined the effect 
of such do~tion  on B cell proliferation. In these studies, 
we incubated LPS-stimulated  B cells with oligonudeotides 
over a range of concentrations,  and assayed proliferation  by 
incorporation  of  [3H]thymidine  after  4  d  of  culture.  As 
shown in Fig.  3 a,  the antisense  oligonucleotide caused  a 
marked dose-dependent decrease in cell proliferation compared 
with the control non-sense (scrambled) oligonudeotides, and, 
a shown in Fig.  3  b, the dose dependence  of this decrease 
in proliferation correlated with that of the decrease in BSAP 
expression  detected  by  EMSA.  The  sense  oligonucleotide 
caused a smaller but reproducible reduction in proliferation, 
consistent with a small reduction in BSAP levels detected by 
densitometry of corresponding EMSA signals  (Fig.  2).  As 
shown in Fig. 4 a, the antiproliferative effect of the antisense 
oligonudeotide was also seen in the culture of BSAP-expressing 
B lymphoma cells (CH12.LX) growing spontaneously.  This 
effect was not due to nonspecific toxicity of the antisense oli- 
gonucleotide, since cell viability was never <85% even in cell 
cultures exposed to high (40 #M) concentrations  of antisense 
oligonudeotide, in which proliferation  was inhibited more 
than 100-fold (data not shown). Furthermore,  proliferation 
of two cell lines lacking measurable BSAP, the murine T cell 
line  EL-4  and  the  myeloma  MOPC-315,  was  virtually 
Figure  3.  (a) Proliferation of spleen B cells stimulated by LPS in the 
presence of oligonudeotides sense and antisense to the BSAP translation 
initiation site and non-sense  (scrambled) oligonucleotides.  Resting spleen 
B cells (5  x  104/well) were stimulated with LPS (20 #g/ml)  and coin- 
cubated with oligonucleotides at different concentrations  as indicated. 
Proliferation was assayed at day 4 by pulsing cells with [3H]thymidine for 
8 h (see Materials  and Methods).  (b) Dose-dependent  reduction of BSAP 
activity in spleen B cells after coincubation  with antisense oligonucleo- 
tide.  Nuclear  proteins were extracted 4 d  after coincubation  and BSAP 
activity was measured by EMSA using a labeled H2A-2.2 probe. Retarded 
EMSA bands were quantified by densitometry,  normalized  to the total 
radioactivity loaded per lane, and compared with noncoincubated  cells. 
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Figure  4.  Effects  of coincubation of BSAP phosphorothioate oligonu- 
cleotides on cell proliferation. (a) B cell lymphoma cells (CHI2.LX),  (b) 
MOPC-315 plasma cells, and (c) T  cell lymphoma cells (EL,4) were cul- 
tured in microwells  (5  x  104 ceLls/well) in the presence of various con- 
centrations of BSAP oligonucleotides.  On day 3, cell proliferation assays 
([3H]thymidine incorporation) were performed as described in Materials 
and Methods. (Filled  columns) Antisense oligonudeotide; (shaded  columns) 
sense oligonucleotide. unaffected by incubation with the antisense oligonudeotide 
(Fig. 4, b and c). Apparently, proliferation in EL-4 and MOPC- 
315 cell lines is regulated by mechanisms independent of BSAP. 
Effect of  BSAP Upregulation on B Cell Proliferation.  In the 
light of the above findings, we sought to determine the effect 
of increased  BSAP expression  on B  cell proliferation. For 
these studies we first constructed a BSAP expression plasmid, 
BCMGSNeo-BSAP,  as described in Materials and Methods. 
We then verified that this cDNA expression plasmid encoded 
functional BSAP by transfecting it into MOPC-315 plasma 
cells, which lack endogenous BSAP, and testing those cells 
for BSAP expression.  As shown in Fig. 5 a, nuclear protein 
extracted from transfected MOPC-315 plasma cells generated 
an EMSA band that comigrated with the endogenous BSAP 
band from LPS-stimulated B cells, whereas nuclear proteins 
extracted from MOPC-315 cells transfected with an empty 
plasmid had no detectable BSAP. In addition, as shown in 
Fig. 5 b, nuclear protein extracted from splenic B cells tran- 
siently transfected with the BSAP expression plasmid gener- 
ated  a BSAP EMSA band of increased intensity. 
The demonstration that the BCMGSNeo-BSAP plasmid 
encoded assayable BSAP protein allowed us to test the effect 
Figure 5.  Expression of BSAP in MOPC-315 plasma cells and purified 
spleen  B cells  transiently  ~  with BCMGSNeo-BSAP  or BCMGSNeo- 
control plasmid. (a) The cDNA expression plasmid BCMGSNeo-BSAP 
or BCMGSNeo-control  plasmid (10 #g) were transfected into the BSAP- 
nonproducing plasma cell line  MOPC-315. Nuclear proteins were extracted 
2 d after transfection and EMSA was performed using a labeled H2A-2.2 
probe. In BCMGSNeo-BSAP-transfected  MOPC-315 cells, a retarded band 
was observed that comigrated with the BSAP signal obtained with nu- 
clear extracts from LPS-stimuhted spleen B cells. (b) Nuclear proteins from 
purified spleen  B cells  transiently transfected  with 10 #g of the BCMGSNeo- 
BSAP plasmid were extracted at the indicated time points after transfec- 
tion and subjected to EMSA analysis  using the H2A-2.2 probe. Nontrans- 
fected purified B cells served as controls. 
of upregulating BSAP levels in B cells. Accordingly, we tran- 
siently transfected spleen B cells with the BCMGSNeo-BSAP 
plasmid and, after 24 h, subjected the cells to various prolifer- 
ation stimuli. We then measured proliferation after 72 h of 
additional incubation. As shown in Fig.  6 a, BCMGNeo- 
BSAP-transfected  B cells exhibited significantly  greater (p 
<0.01)  proliferation than B  cells transfected  with control 
plasmids.  To confirm and amplify these results, we also de- 
termined LPS-induced proliferation in BCMGSNeo-BSAP- 
transfected versus control plasmid-transfected cells in cell popu- 
lations enriched for transfected and nontransfected cells. En- 
richment of transfected and nontransfected cells was accom- 
plished by electroporation in the presence of dextran-FITC 
followed by cell sorting and isolation of FITC-High and FITC- 
Low cells (see Materials and Methods). The efficiency of this 
method was verified in a control experiment in which a pSV- 
3-galactosidase control vector was transfected in the presence 
of dextran-FITC and 3-galactosidase  activity was measured 
in FITC-High and FITC-Low cell populations. 3-galactosidase 
activity was detected in 40% of FITC-High and 5% of the 
FITC-Low cell populations, indicating an eightfold enrich- 
ment of transfected cells in the FITC-High cell population 
compared with the FITC-Low cell population. As shown in 
Fig. 6, b and c, we found that in the FITC-High cell popula- 
tion, transfi.~'tion  with BCMGSNeo-BSAP caused significantly 
higher proliferation than transfection with control plasmid. 
In contrast, in FITC-Low cell population, no significant differ- 
ences between BCMGSNeo-BSAP and control transfected cells 
were observed.  Taken together, these results show that up- 
regulation of BSAP expression in spleen B cells results in sub- 
stantially increased B cell proliferation responses, regardless 
of the method of cell stimulation. 
In further studies we determined the effect of de novo BSAP 
expression on MOPC-315 plasma cells, which as mentioned 
above, do not normally express BSAP. In these studies, equal 
numbers of BCMGSNeo-BSAP-transfected and control plas- 
mid-transfected MOPC-315 plasma cells were placed into 
microwells, and after 72 h, proliferation of cells was assessed 
by [3H]thymidine uptake. Significantly more [3H]thymidine 
uptake occurred in plasma cells transfected with the BSAP- 
expressing plasmid (52,118 _+ 459) than in plasma cells trans- 
fected with the non-BSAP-expressing plasmid (29,078  _ 
2763)  (p <0.005). 
Effect of Downregulation of BSAP by Antisense  Oligonucleo- 
tide on B  Cell Isotype Switch.  To explore further the role of 
BSAP expression on B cell function, we determined the effect 
of BSAP downregnlation on B cell isotype switch. This was 
of considerable interest because binding sites for BSAP have 
recently been found 5' to and within the switch region of 
Ig H chain genes (4-6) and in the 3'ol enhancer (7, 8), sug- 
gesting that BSAP plays a role in H chain isotype switching. 
In these studies,  we first  stimulated purified resting spleen 
B calls with LPS and cytokines in the presence or absence 
of the phosphorothioate oligonucleotides for 4 d. We then 
stained the cells with isotype-specific antibodies to determine 
the percentage of various  surface Ig-positive B cells present 
at the end of the culture period. As shown in the representa- 
tive experiment depicted in Fig.  7,  the incubation of cells 
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BCMGSNesycontrol phsmid (shaded 
bar) when cells are cocultured with 
L ceils (LcD~2), L cells transfected 
with a phsmid expressing  CD40 
ligand  (LcD40L),  and  L  calls 
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three  experiments).  The  baseline 
counts of BCMGSNeo-BSAP and 
control plasmid-transfected B cells 
were 5,458  +_  69.0 and 7,246  + 
89.1,  respectively.  (b and c) LPS- 
stimulation of spleen B cells trans- 
lated  with  BCMGSNeo-BSAP 
(solid bar) or control phsmid (shaded 
bar) and enriched by cotransfection 
of dextran-FITC followed by cell 
sorting (see Materials and Methods). 
Fluorescence-high  (b) and -low (c) 
cells  were  seeded  at  5  x  104 
cells/well and stimulated with var- 
ious  concentrations  of  LPS. 
(Asterisks) p <0.01. 
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Figure 7.  Effect of BSAP oligonudeo- 
tides on B cell isotype switching. High den- 
sity (resting) spleen cells were purified and 
cultured (at 10S/m1) in media containing 
LPS (20 #g/m1) and rib4 (400 U/m1) in 
the presence of indicated oligonudeotides 
(30 #M) for 4 d. On day 4, the cells were 
stained  with  PE-labeled  anti-IgM  and 
FITC-labded anti-IgG1, after which flow 
cytometry was performed in an EPICS 753 
flow cytometer.  Percent  slgGl-positive B 
cells are indicated. 
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centage of slgG1 + cells in B cells cultured with LPS plus 
IL-4. Similarly, reduced numbers of slgG2a B cells were found 
in cells cultured with LPS and IFN-7, and reduced numbers 
of slgG3 + B  cells were noted in cells cultured with LPS 
alone. Thus, downregulation of BSAP led to reduced B cell 
isotype switching of B cells treated by LPS plus cytokines. 
Discussion 
The B cell-specific activator protein BSAP is a mammalian 
homolog of the sea urchin DNA-binding protein TSAP (tissue- 
specific  transcription  activator  protein),  a  regulator  of a 
nonallelic pair of late histone genes (H2A-2 and H2B-2) (26). 
Several findings suggest that BSAP is a transcriptional regu- 
lator of B cell-specific genes. For instance, BSAP has been 
shown to regulate transcription of the CD19 gene, a gene 
encoding a B cell transmembrane glycoprotein involved in 
cell activation (27).  In addition, BSAP is probably identical 
to EBB-l, a protein which has been shown to regulate tran- 
scription of the early B cell signal transduction molecules, 
Vp~,B1 and )~5 (3). Finally,  BSAP has been shown to repress 
the Ig H chain 3'cx enhancer at early stages of B cell differen- 
tiation (7, 8), with probable but as yet unknown effects on 
Ig gene transcription. The fact that BSAP binds to various 
intronic regions of the Ig constant region gene segments leads 
to the expectation that it also plays a role in regulating iso- 
type switching, but this remains to be proven. 
In this study, we provide several kinds of evidence for a 
new role for BSAP as a regulator of B cell proliferation. Ini- 
tially, we showed that stimulation of spleen B cells by three 
representative mechanisms resulted in an increase in BSAP 
expression that correlated with an increase in B cell prolifera- 
tion. We then demonstrated that down- or upregulation of 
BSAP expression during B cell stimulation led to decreased 
or increased cell proliferation, respectively. Downregulation 
of BSAP levels, induced by exposure of stimulated B cells 
to an antisense oligonucleotide, resulted in a more than 100- 
fold reduction in the proliferation of LPS-activated normal 
B cells, as well as greatly reduced proliferation of spontane- 
ously growing lymphoma B cells (CH12.LX B cells). This 
effect of the antisense oligonucleotide was shown by previ- 
ously established criteria (28) to be both effective and specific: 
(a) the EMSA levels of functional BSAP protein were greatly 
reduced in cells exposed to the antisense oligonudeotide; (b) 
exposure of B cells to the antisense oligonudeotide had no 
effect on a nontargeted protein (AP-1);  (c) treatment of B 
cells with non-sense (scrambled) oligonucleotides only mini- 
mally affected  BSAP levels; and (d) antisense oligonucleotide 
treatment had no effect on proliferation of two cell lines that 
lack endogenous BSAP. Finally, we found that upregulation 
of BSAP in spleen B cells or de novo expression of BSAP 
in MOPC-315 plasma cells, achieved by transfection of a BSAP 
expression plasmid, leads to a significant increase in cell prolifer- 
ation. In control experiments using a transfected fl-galactosi- 
dase expression plasmid, we found that our protocol of elec- 
troporation in the presence of dextran-FITC followed by cell 
sorting to obtain the FITC-High cell population enriched 
transfected cells to only 40% of the FITC-High cell popula- 
tion. Thus the increased proliferation we observed probably 
underestimates the ability of increased BSAP levels to upregu- 
late proliferation. Taken together, these findings demonstrate 
that either down- or upregulation of BSAP induced a de- 
crease or increase in B cell proliferation, respectively. As such, 
they provide strong evidence that BSAP is an important and 
rate-limiting factor in B cell proliferation. 
Our findings on the relation of BSAP to B cell prolifera- 
tion place BSAP in the company of several protooncogene 
products including c-Jos, c-myc, and c-m),b (29-34),  which 
have also been shown by techniques similar to the ones used 
here to regulate cell proliferation. In addition, the effect of 
BSAP on cell proliferation can be related to recent findings 
which indicate that deregulation of several PAX genes pro- 
motes malignant transformation (35).  Of interest, this on- 
cogenesis depended on a functional paired domain that is 
unique to PAX genes and that mediates DNA binding of 
PAX gene products. At the moment it is not known which 
gene or genes mediate BSAP's effect on B cell proliferation. 
It is clear, however, that this function is very different from 
that of the above noted oncogenes or other PAX genes since 
the proliferative effect of BSAP is B cell specific. 
Because BSAP has known binding sites near various switch 
regions, BSAP may play a role in the regulation of isotype 
switching. In fact, we found that downregulation of BSAP 
by antisense oligonucleotides does inhibit isotype switching 
induced by various stimuli, most notably, LPS plus IL-4. How- 
ever, it is not clear whether this effect is mediated by BSAP 
binding sites in the Ig H  chain locus or by a more general 
effect on cell proliferation, since proliferation has been shown 
to be a prerequisite of switch rearrangement (36,  37). 
Recently, we (8) and Singh and Birshtein (7) have shown 
that BSAP binding sites in the Ig H chain 3'o~ enhancer have 
a negative effect on enhancer activity. For instance, in the 
experiments we performed, expression of a reporter gene driven 
by the 3'ol enhancer plus ~c L chain promoter was inhibited 
by cotransfection of a BSAP expression plasmid in MOPC- 
315 plasma cells.  The fact that BSAP may repress the 3'c~ 
enhancer and thereby downregulate Ig gene transcription 
would explain why BSAP is not expressed in plasma cells, 
cells whose main function is high-rate Ig gene transcription 
(and subsequent Ig secretion). In summary, it appears  that 
BSAP effects are quite complex and are dependent on the stage 
of B cell development. Early on, BSAP is necessary for B 
call proliferation and differentiation. Later,  after the B cell 
has terminally differentiated, BSAP is downregulated in order 
to enable high level Ig gene expression. In either case, the 
function of BSAP is closely linked to the two most impor- 
tant functions of B cells: proliferation and synthesis of Igs. 
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